Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3536 - Breast cancer in young women survivors of pediatric cancer


09 Oct 2016


Poster display


Carmen Salvador Coloma


Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385


C. Salvador Coloma1, A. Cañete2, J. Balaguer2, L. Montero3, R.M. Viguer4, A. Santaballa1

Author affiliations

  • 1 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 2 Pediatrics Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 3 Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 4 Radiology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES


Abstract 3536


Patients cured of a pediatric cancer have shown increased risk of second tumors. Women long-term survivors have a significantly increased risk of developing breast cancer (BC) at a young age. Screening programs for early detection of BC are well-established in healthy women. On the contrary, there is a scarcity of guidelines for young women cured of a pediatric cancer. We try to develop a multidisciplinary screening program for our survivors at risk.


Patients were identified from Pediatric Oncology Department at the University Hospital La Fe. The cohort consists of young women with a prior diagnosis of a pediatric tumor, if treatment had included chest RT and/or high dose of alkylating chemotherapy before bone marrow transplantation. Imaging studies were performed according to age. If any suspicious lesion was detected, the patient was transferred to the Breast Unit in Oncology.


17 women (10 Hodgkin Lymphoma, 4 Non Hodgkin Lymphoma and 3 Ewing´s Sarcoma) were contacted. 4 women refused to be included (2 due to psychological reasons, 1 pregnancy, 1 just-diagnosed with BC). Median age was 27 years and median time since end-of-treatment was 14.5 years. The initial treatment was chemotherapy (CT) alone in 6 patients (46.2%) and combined CT and radiotherapy (RT) in 7 (53.8%). 7 cases were irradiated (5 Hodgkińs Lymphoma, 1 Non Hodgkińs Lymphoma, 1 Ewing). The median dose of mediastinal RT was 22.6 Gy (range 15-25.2 Gy). Breast exams were normal. The MRI were performed in 8 of 13 patients. It revealed a suspicious lesion in 1 patient (BI-RADS 4) and benign lesions in 3 patients (BI-RADS 2). MRI studies of the remaining 4 patients were normal, without findings. Benign lesions were fibroids. The patient with the malignant lesion was an invasive ductal carcinoma with positive hormonal receptors and negative Her-2 neu (pT1b N1a(sn) M0, grade II, ki67 15%).


We have developed a complete early-detection-BC program for our population, that did not exist previously. Although a small number of women were involved, two BC were detected. We have shown the potential benefit of screening BC program, but the challenge to increase the attracting high-risk patients to these programs.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitario y Politécnico La Fe


GVA grant.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings